ATE507828T1 - Neue pyrrole mit hypolipidämischer und hypocholesterischer aktivität, herstellungsverfahren, diese enthaltende pharmazeutische zusammensetzungen und deren medizinische verwendung - Google Patents

Neue pyrrole mit hypolipidämischer und hypocholesterischer aktivität, herstellungsverfahren, diese enthaltende pharmazeutische zusammensetzungen und deren medizinische verwendung

Info

Publication number
ATE507828T1
ATE507828T1 AT02751609T AT02751609T ATE507828T1 AT E507828 T1 ATE507828 T1 AT E507828T1 AT 02751609 T AT02751609 T AT 02751609T AT 02751609 T AT02751609 T AT 02751609T AT E507828 T1 ATE507828 T1 AT E507828T1
Authority
AT
Austria
Prior art keywords
hypocholesteric
hypolipidemic
activity
preparation
pharmaceutical compositions
Prior art date
Application number
AT02751609T
Other languages
English (en)
Inventor
Braj Bhushan Lohray
Vidya Bhushan Lohray
Vijay Kumar Barot
Saurin Khimshankar Raval
Preeti Saurin Raval
Sujay Basu
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Application granted granted Critical
Publication of ATE507828T1 publication Critical patent/ATE507828T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F3/00—Input arrangements for transferring data to be processed into a form capable of being handled by the computer; Output arrangements for transferring data from processing unit to output unit, e.g. interface arrangements
    • G06F3/14—Digital output to display device ; Cooperation and interconnection of the display device with other functional units
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09G—ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION
    • G09G5/00—Control arrangements or circuits for visual indicators common to cathode-ray tube indicators and other visual indicators
    • G09G5/36—Control arrangements or circuits for visual indicators common to cathode-ray tube indicators and other visual indicators characterised by the display of a graphic pattern, e.g. using an all-points-addressable [APA] memory
    • G09G5/363—Graphics controllers
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F3/00—Input arrangements for transferring data to be processed into a form capable of being handled by the computer; Output arrangements for transferring data from processing unit to output unit, e.g. interface arrangements
    • G06F3/14—Digital output to display device ; Cooperation and interconnection of the display device with other functional units
    • G06F3/1423—Digital output to display device ; Cooperation and interconnection of the display device with other functional units controlling a plurality of local displays, e.g. CRT and flat panel display
    • G06F3/1438—Digital output to display device ; Cooperation and interconnection of the display device with other functional units controlling a plurality of local displays, e.g. CRT and flat panel display using more than one graphics controller
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09G—ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION
    • G09G2360/00—Aspects of the architecture of display systems
    • G09G2360/12—Frame memory handling
    • G09G2360/122—Tiling

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Theoretical Computer Science (AREA)
  • Obesity (AREA)
  • General Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Human Computer Interaction (AREA)
  • Biomedical Technology (AREA)
  • Computer Hardware Design (AREA)
  • Neurosurgery (AREA)
  • Computer Graphics (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
AT02751609T 2001-07-26 2002-07-25 Neue pyrrole mit hypolipidämischer und hypocholesterischer aktivität, herstellungsverfahren, diese enthaltende pharmazeutische zusammensetzungen und deren medizinische verwendung ATE507828T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN711MU2001 2001-07-26
PCT/IN2002/000155 WO2003009841A1 (en) 2001-07-26 2002-07-25 Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine

Publications (1)

Publication Number Publication Date
ATE507828T1 true ATE507828T1 (de) 2011-05-15

Family

ID=11097270

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02751609T ATE507828T1 (de) 2001-07-26 2002-07-25 Neue pyrrole mit hypolipidämischer und hypocholesterischer aktivität, herstellungsverfahren, diese enthaltende pharmazeutische zusammensetzungen und deren medizinische verwendung

Country Status (31)

Country Link
US (6) US6987123B2 (de)
EP (1) EP1414439B1 (de)
JP (2) JP4313194B2 (de)
KR (2) KR20060094545A (de)
CN (1) CN100450477C (de)
AP (1) AP1808A (de)
AR (1) AR036347A1 (de)
AT (1) ATE507828T1 (de)
AU (1) AU2002355205B2 (de)
BR (1) BRPI0211665B8 (de)
CA (1) CA2454863C (de)
CO (1) CO5390079A1 (de)
CY (1) CY1111876T1 (de)
DE (1) DE60239939D1 (de)
DK (1) DK1414439T3 (de)
EA (1) EA006858B1 (de)
ES (1) ES2366279T3 (de)
HR (1) HRP20040138B1 (de)
IL (1) IL160042A (de)
MX (1) MXPA04000758A (de)
MY (1) MY140057A (de)
NO (1) NO326698B1 (de)
NZ (2) NZ545896A (de)
OA (1) OA12702A (de)
PL (1) PL224397B1 (de)
PT (1) PT1414439E (de)
RS (1) RS51837B (de)
SI (1) SI1414439T1 (de)
UA (1) UA76992C2 (de)
WO (1) WO2003009841A1 (de)
ZA (1) ZA200400563B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6987123B2 (en) * 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US20040047919A1 (en) * 2002-06-13 2004-03-11 Board Of Regents, The University Of Texas System Methods and compositions involving aldose reductase inhibitors
US20050288373A1 (en) * 2002-10-24 2005-12-29 Ron Eyal S Methods of treating various conditions by administration of sustained release L-arginine
US20040248972A1 (en) * 2003-05-16 2004-12-09 Ambit Biosciences Corporation Compounds and uses thereof
US20050182125A1 (en) * 2003-05-16 2005-08-18 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
CA2523808A1 (en) * 2003-05-16 2004-12-23 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
US7767152B2 (en) * 2003-08-11 2010-08-03 Sakura Finetek U.S.A., Inc. Reagent container and slide reaction retaining tray, and method of operation
US9518899B2 (en) * 2003-08-11 2016-12-13 Sakura Finetek U.S.A., Inc. Automated reagent dispensing system and method of operation
US7744817B2 (en) * 2003-08-11 2010-06-29 Sakura Finetek U.S.A., Inc. Manifold assembly
JP4703649B2 (ja) * 2004-07-30 2011-06-15 エグゼリクシス， インコーポレイテッド 薬学的因子としてのピロール誘導体
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
EP1999119A2 (de) 2006-02-15 2008-12-10 Abbott Laboratories Neue acetyl-coa-carboxylase-(acc)-inhibitoren und deren verwendung bei diabetes, adipositas und stoffwechselsyndrom
CA2641766A1 (en) 2006-02-15 2007-08-23 Abbott Laboratories Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
US8459509B2 (en) 2006-05-25 2013-06-11 Sakura Finetek U.S.A., Inc. Fluid dispensing apparatus
EP2139330B1 (de) 2007-03-23 2014-09-24 The Board of Regents of The University of Texas System Verfahren mit aldose-reduktase-inhibitoren
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
CN104672202B (zh) * 2010-08-18 2017-07-28 萨穆梅德有限公司 作为联蛋白信号通路激活剂的二酮与羟基酮
AU2015258299B2 (en) * 2010-08-18 2017-10-19 Samumed, Llc Diketones and hydroxyketones as catenin signaling pathway activators
RS54735B1 (sr) 2011-01-31 2016-10-31 Cadila Healthcare Ltd Tretman za lipodistrofiju
AU2015268725B2 (en) * 2011-01-31 2016-10-20 Zydus Lifesciences Limited Treatment for lipodystrophy
US8752732B2 (en) 2011-02-01 2014-06-17 Sakura Finetek U.S.A., Inc. Fluid dispensing system
JP5971657B2 (ja) * 2011-04-20 2016-08-17 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素環誘導体
US8580568B2 (en) 2011-09-21 2013-11-12 Sakura Finetek U.S.A., Inc. Traceability for automated staining system
US8932543B2 (en) 2011-09-21 2015-01-13 Sakura Finetek U.S.A., Inc. Automated staining system and reaction chamber
US8754084B2 (en) 2012-03-27 2014-06-17 The Board Of Trustees Of The University Of Illinois Therapeutic methods and agents for treating myotonic dystrophy
TR201901496T4 (tr) 2013-02-22 2019-02-21 Samumed Llc Wnt/Beta -katenin sinyal yolağı aktivatörleri olarak gamma-diketonları.
MA38385A1 (fr) 2013-04-22 2017-09-29 Cadila Healthcare Ltd Nouvelle composition pour la stéatose hépatique non alcoolique (nafld)
MX2015016403A (es) 2013-05-30 2016-04-11 Cadila Healthcare Ltd Proceso para la preparacion de pirroles que tienen actividad hipolipidemica e hipocolesterolemica.
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (de) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
IN2013MU02828A (de) 2013-08-29 2015-07-03 Cadila Healthcare Ltd
IN2013MU02905A (de) 2013-09-06 2015-07-03 Cadila Healthcare Ltd
US9376421B2 (en) 2014-08-08 2016-06-28 The Board Of Trustees Of The University Of Illinois Compounds and methods for myotonic dystrophy therapy
DK3206686T3 (da) 2014-08-20 2019-12-16 Samumed Llc Gamma-diketoner til behandling og forebyggelse af ældning af huden og rynker
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
WO2017089980A1 (en) 2015-11-26 2017-06-01 Cadila Healthcare Limited Dual ppar modulators for the treatment of diabetic retinopathy and diabetic eye diseases
WO2017089979A1 (en) 2015-11-26 2017-06-01 Cadila Healthcare Limited Dual ppar modulators for the treatment of diabetic nephropathy and related diseases
EP3551180B1 (de) 2016-12-09 2021-09-29 Cadila Healthcare Limited Behandlung von primärer biliärer cholongitis
US11242326B2 (en) 2017-08-25 2022-02-08 The Board Of Trustees Of The University Of Illinois Multivalent ligand for myotonic dystrophy
WO2020128815A1 (en) 2018-12-18 2020-06-25 Cadila Healthcare Limited Saroglitazar for the treatment of hepatocellular carcinoma
CN110372677B (zh) * 2019-07-25 2021-01-05 浙江海森药业股份有限公司 一种无溶剂法制备阿托伐他汀关键中间体l1的方法
WO2021220236A1 (en) * 2020-05-01 2021-11-04 Cadila Healthcare Limited Pharmaceutical compositions for combination therapy
US12201611B2 (en) 2020-07-24 2025-01-21 Zydus Lifesciences Limited Composition comprising high purity pyrrole derivative and method for preparation thereof
AU2021391968A1 (en) * 2020-12-03 2023-06-22 Delta 4 Gmbh Saroglitazar and myristic acid for use in the treatment of focal segmental glomerulosclerosis (fsgs)

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
PL174610B1 (pl) 1992-07-03 1998-08-31 Smithkline Beecham Plc Nowe związki heterocykliczne
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
GB9311644D0 (en) 1993-06-05 1993-07-21 Smithkline Beecham Plc Novel compounds
US5387613A (en) 1993-07-23 1995-02-07 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
WO1996004261A1 (en) 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
CN1094940C (zh) 1995-04-28 2002-11-27 第一制药株式会社 具有抗肿瘤活性的紫杉酚衍生物
AU706628B2 (en) 1995-07-03 1999-06-17 Sankyo Company Limited Treatment of arteriosclerosis and xanthoma
JP3220373B2 (ja) 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
GB9600464D0 (en) * 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
DE19607953A1 (de) 1996-03-01 1997-09-04 Kalle Nalo Gmbh Nach dem Aminoxidverfahren hergestellte Nahrungsmittelhüllen auf Cellulosebasis
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
ZA973848B (en) 1996-05-06 1997-12-02 Reddy Research Foundation Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them.
ZA973850B (en) 1996-05-06 1997-12-02 Reddy Research Foundation Novel antidiabetic compounds having hypolipidaemic, anti-hypertensive properties, process for their preparation and pharmaceutical compositions containing them.
US5885997A (en) 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
KR100579765B1 (ko) * 1996-07-01 2006-12-28 닥터 레디스 레보러터리즈 리미티드 신규헤테로고리형화합물의제조방법,이를함유하는약제조성물및당뇨병및이와관련된질병의치료에있어서그의용도
JP2000514807A (ja) 1996-07-12 2000-11-07 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー レプチン耐性の新規な治療
DE69723070T2 (de) 1996-12-24 2005-02-17 Daewoo Motor Co., Ltd. Abgasrückführventil für brennkraftmaschine
US6011036A (en) 1997-04-15 2000-01-04 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic hypolipidemic antihypertensive properties process for their preparation and pharmaceutical compositions containing them
US6011031A (en) 1997-05-30 2000-01-04 Dr. Reddy's Research Foundation Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them
CZ273997A3 (cs) 1997-09-02 1999-02-17 Rieter Elitex A.S. Spřádací ústrojí rotorového dopřádacího stroje
CN100471832C (zh) * 1997-09-11 2009-03-25 法玛西雅厄普约翰美国公司 用于制备蛋白酶抑制剂的化合物
DE69815008T2 (de) 1997-09-19 2004-04-01 Ssp Co., Ltd. Alfa-substituierte Phenylpropionsäurederivate und diese enthaltende Arzneimittel
US6130214A (en) * 1997-10-27 2000-10-10 Dr. Reddy's Research Foundation Benzothiazin and benzoxazin derivatives; their preparation and uses
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
US6054453A (en) * 1997-10-27 2000-04-25 Redd's Research Foundation Tricyclic compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them
US6369067B1 (en) 1997-10-27 2002-04-09 Dr. Reddy's Research Foundation Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
US6265401B1 (en) 1997-10-27 2001-07-24 Reddy-Cheminor, Inc. Bicyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
US6444816B1 (en) 1997-10-27 2002-09-03 Dr. Reddy's Research Foundation Fused 7-oxo-pyrimidinyl compounds, preparation, composition and use thereof
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
EP1051403A1 (de) 1998-01-29 2000-11-15 Dr. Reddy's Research Foundation Alkansaüren und deren verwendung in heilmittel, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
DE69828445D1 (de) 1998-04-23 2005-02-03 Reddys Lab Ltd Dr Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
JP2003517434A (ja) 1998-05-05 2003-05-27 セプレイサー インコーポレイテッド ヒドロキシオメプラゾール組成物及びその使用
CN100357281C (zh) 1998-05-27 2007-12-26 雷迪实验室有限公司 双环化合物、其制备方法和包含它们的药物组合物
SE9801990D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl propionic acid derivatives and analogs
US6589969B1 (en) 1998-10-16 2003-07-08 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
WO2000023445A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
US6248781B1 (en) 1998-10-21 2001-06-19 Novo Nordisk A/S Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR)
EP1123269A1 (de) 1998-10-21 2001-08-16 Novo Nordisk A/S Neuartige verbindungen, ihre herstellung und ihre verwendung
WO2000023451A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
CN1208321C (zh) 1999-07-20 2005-06-29 道农业科学公司 杀真菌的杂环芳族酰胺和它们的组合物、使用方法和制备
US6312113B1 (en) * 1999-10-29 2001-11-06 Marconi Data Systems Inc. Ink circulation system
WO2001053257A2 (en) * 2000-01-19 2001-07-26 Cadila Healthcare Ltd. Compounds having hypolipedemic and hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them
US6569901B2 (en) 2000-01-28 2003-05-27 Novo Nordisk A/S Alkynyl-substituted propionic acid derivatives, their preparation and use
DE60128475T2 (de) 2000-07-25 2008-02-07 Merck & Co., Inc. N-substituierte indole mit anwendung in der behandlung von diabetes
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine

Also Published As

Publication number Publication date
RS51837B (sr) 2012-02-29
US20070238776A1 (en) 2007-10-11
CY1111876T1 (el) 2015-11-04
PL368289A1 (en) 2005-03-21
US6987123B2 (en) 2006-01-17
DE60239939D1 (de) 2011-06-16
EA200400226A1 (ru) 2004-08-26
WO2003009841A1 (en) 2003-02-06
BR0211665A (pt) 2005-01-11
ES2366279T3 (es) 2011-10-18
SI1414439T1 (sl) 2011-08-31
CO5390079A1 (es) 2004-04-30
NZ550375A (en) 2008-09-26
UA76992C2 (uk) 2006-10-16
US20040186099A1 (en) 2004-09-23
NO20040301L (no) 2004-03-24
JP2005503367A (ja) 2005-02-03
NZ545896A (en) 2008-06-30
MXPA04000758A (es) 2004-07-08
ZA200400563B (en) 2004-10-29
CN100450477C (zh) 2009-01-14
KR100667710B1 (ko) 2007-01-12
US8558009B2 (en) 2013-10-15
OA12702A (en) 2006-06-23
JP4313194B2 (ja) 2009-08-12
US8110598B2 (en) 2012-02-07
PL224397B1 (pl) 2016-12-30
IL160042A (en) 2012-04-30
NO326698B1 (no) 2009-02-02
PT1414439E (pt) 2011-07-27
US20030236254A1 (en) 2003-12-25
AP2004002973A0 (en) 2004-03-31
AU2002355205B2 (en) 2004-11-18
EA006858B1 (ru) 2006-04-28
AR036347A1 (es) 2004-09-01
CA2454863C (en) 2010-07-06
EP1414439B1 (de) 2011-05-04
US7041837B2 (en) 2006-05-09
CN1558758A (zh) 2004-12-29
MY140057A (en) 2009-11-30
BRPI0211665B8 (pt) 2021-05-25
IL160042A0 (en) 2004-06-20
HRP20040138B1 (hr) 2016-12-02
YU17404A (sh) 2006-08-17
EP1414439A1 (de) 2004-05-06
KR20040023685A (ko) 2004-03-18
DK1414439T3 (da) 2011-07-18
BR0211665B1 (pt) 2017-10-31
JP2009102423A (ja) 2009-05-14
US20080188402A1 (en) 2008-08-07
US20110275669A1 (en) 2011-11-10
US20030199498A1 (en) 2003-10-23
KR20060094545A (ko) 2006-08-29
AP1808A (en) 2007-12-18
HRP20040138A2 (en) 2005-02-28
US7323491B2 (en) 2008-01-29
CA2454863A1 (en) 2003-02-06
US8212057B2 (en) 2012-07-03

Similar Documents

Publication Publication Date Title
ATE507828T1 (de) Neue pyrrole mit hypolipidämischer und hypocholesterischer aktivität, herstellungsverfahren, diese enthaltende pharmazeutische zusammensetzungen und deren medizinische verwendung
DE60142890D1 (de) 3-aminoazetidinderivate enthaltende pharmazeutische zusammensetzungen, diese derivate und deren herstellung
BRPI0013391B8 (pt) uso de polipeptídeos bcma na preparação de uma composição farmacêutica para tratar uma doença autoimune ou um distúrbio linfoproliferativo de célula b
ATE309206T1 (de) Schwefel-substituierte sulfonylaminocarbonsäure n-arylamide, ihre herstellung, ihre anwendung und diese enthaltende pharmazeutische zusammensetzungen
ATE321769T1 (de) Neue aromatische fluorglycosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
ATE368041T1 (de) Neue pyrrolderivate als pharmazeutische mittel
ATE389019T1 (de) Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen
ATE204754T1 (de) Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie
DE60208351D1 (de) Glukopyranosyloxybenzylbenzolderivate und deren medizinische verwendung
DE60237580D1 (de) Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
EE200300145A (et) Asa- ja polüasanaftalenüülkarboksamiidid ja farmatseutiline kompositsioon
ATE323713T1 (de) Neue heterocyclische fluorglykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EE04464B1 (et) Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE05104B1 (et) Asetidiini derivaadid, nende valmistamise meetodid ja farmatseutiline kompositsioon
EE200300207A (et) Heterotsüklüülalküülpiperidiini derivaadid, nendevalmistamismeetodid ja farmatseutiline kompositsioon
DE60121813D1 (de) Neue chinuclidinderivate und medizinische zusammensetzungen, die diese verbindungen enthalten
DE69816471D1 (de) Pyrimidinon verbindungen und diese enthaltende pharmazeutische zusammenstellungen
DE60014918D1 (de) Indol-verbindungen, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische zusammensetzungen und ihre medizinische anwendung
EE200200298A (et) Asendatud ftalotsüaniinid ja nende lähteühendid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja materjal
ATA13842001A (de) Chitosan-thio-alkyl-amidin konjugate und deren kosmetische sowie pharmazeutische verwendung
DE69927033D1 (de) 4-aminopyridinderivate, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen
EE200100653A (et) Indolüülpiperidiinühendid, nende valmistamismeetod, kompositsioon ja nende kasutamine
DE602004017463D1 (de) Diphenylpyridinderivate, deren herstellung und deren therapeutische anwendung
ATE312828T1 (de) Acylaminothiazolderivate, deren herstellung und deren therapeutische verwendung
DE60009804D1 (de) Heteroaryl-substituierte Pyrrole, Verfahren zu ihrer Herstellung und ihre therapeutische Anwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1414439

Country of ref document: EP